A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study of Etanercept on a Background Non Steroidal Anti-Inflammatory Drug in the Treatment of Adult Subjects With Non Radiographic Axial Spondyloarthritis With a 92 Week Open Label Extension

Trial Profile

A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study of Etanercept on a Background Non Steroidal Anti-Inflammatory Drug in the Treatment of Adult Subjects With Non Radiographic Axial Spondyloarthritis With a 92 Week Open Label Extension

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms AS EARLY; EMBARK
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Jun 2017 Results (n=361) of a study assessing change in sacroiliac joint structural radiographic damage after 2 years of Etanercept using patient data from NCT01258738 and NCT01648907 trials, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results (n=238) of a study assessing a structural effect of etanercept in axial spondyloarthritis over 2 years using patient data from NCT01258738 and NCT01648907 trials, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results of post-hoc analysis presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top